Vamil Divan
Stock Analyst at Guggenheim
(4.53)
# 248
Out of 4,876 analysts
236
Total ratings
62.73%
Success rate
14.86%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences | Upgrades: Buy | $14 | $9.72 | +44.03% | 1 | Jun 16, 2025 | |
| SVRA Savara | Maintains: Buy | $9 → $8 | $2.18 | +266.97% | 1 | May 28, 2025 | |
| AMGN Amgen | Assumes: Neutral | $288 | $280.10 | +2.82% | 1 | May 20, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $86 | $65.01 | +32.29% | 11 | May 12, 2025 | |
| VALN Valneva SE | Maintains: Buy | $15 → $14 | $5.76 | +143.27% | 1 | May 8, 2025 | |
| ABBV AbbVie | Maintains: Buy | $214 → $216 | $186.25 | +15.97% | 26 | Apr 29, 2025 | |
| UNCY Unicycive Therapeutics | Initiates: Buy | $60 | $6.85 | +775.91% | 1 | Apr 21, 2025 | |
| MRK Merck & Co. | Reiterates: Buy | $115 | $78.92 | +45.72% | 14 | Apr 17, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Buy | $47 | $15.04 | +212.50% | 8 | Apr 14, 2025 | |
| JNJ Johnson & Johnson | Reiterates: Neutral | n/a | $152.95 | - | 15 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $17.20 | +80.23% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.69 | +272.44% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $24.30 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $22.82 | +167.31% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $101 | $100.80 | +0.20% | 6 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $13.60 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.72 | +731.66% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $9.27 | +115.66% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.66 | +3,866.44% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.75 | +1,107.73% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.24 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $22.07 | -13.91% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $126.83 | -22.73% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $28.87 | +17.77% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.70 | +488.24% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $105.55 | -53.57% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $786.69 | -54.75% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $4.65 | +29.03% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $14.48 | +963.90% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $9.24 | +62.34% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.99 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $16.85 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $3.96 | +278.79% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $46.69 | +30.65% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $1.05 | +9,756.46% | 3 | Jan 17, 2018 |
Jade Biosciences
Jun 16, 2025
Upgrades: Buy
Price Target: $14
Current: $9.72
Upside: +44.03%
Savara
May 28, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.18
Upside: +266.97%
Amgen
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $280.10
Upside: +2.82%
ANI Pharmaceuticals
May 12, 2025
Reiterates: Buy
Price Target: $86
Current: $65.01
Upside: +32.29%
Valneva SE
May 8, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $5.76
Upside: +143.27%
AbbVie
Apr 29, 2025
Maintains: Buy
Price Target: $214 → $216
Current: $186.25
Upside: +15.97%
Unicycive Therapeutics
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $6.85
Upside: +775.91%
Merck & Co.
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $78.92
Upside: +45.72%
Travere Therapeutics
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $15.04
Upside: +212.50%
Johnson & Johnson
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $152.95
Upside: -
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $17.20
Upside: +80.23%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.69
Upside: +272.44%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $24.30
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $22.82
Upside: +167.31%
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $100.80
Upside: +0.20%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $13.60
Upside: -
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $0.72
Upside: +731.66%
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $9.27
Upside: +115.66%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.66
Upside: +3,866.44%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.75
Upside: +1,107.73%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.24
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $22.07
Upside: -13.91%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $126.83
Upside: -22.73%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $28.87
Upside: +17.77%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.70
Upside: +488.24%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $105.55
Upside: -53.57%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $786.69
Upside: -54.75%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $4.65
Upside: +29.03%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $14.48
Upside: +963.90%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $9.24
Upside: +62.34%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $27.99
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $16.85
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $3.96
Upside: +278.79%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $46.69
Upside: +30.65%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $1.05
Upside: +9,756.46%